NovoMedix discovers and develops proprietary small molecules that target key regulatory pathways in incurable diseases. Our initial focus is metastatic triple negative breast cancer (mTNBC) and treatment of cardiopulmonary injuries.

Cancer: Metastatic Triple Negative Breast Cancer (mTNBC)

mTNBC is considered incurable with a median survival of 8-13 months. These first-in-class drug candidates effectively treat primary and metastatic TNBC alone or in combination with other cancer drugs (including checkpoint inhibitors) in animal models by blocking the pro-survival and immune suppressive effects of the tumor microenvironment that drive cancer progression. In addition, NM drugs reduce therapy-induced cardiotoxicity and thereby improve survival and long term outcomes for TNBC patients.


Cardio-Oncology is an emerging subspecialty that addresses the profound effects of malignancies and oncological treatments on the cardiovascular system that often lead to heart failure mortality. While cardiovascular damage can occur with numerous cancer therapies, anthracyclines like doxorubicin (DOX, Adriamycin), the frontline treatment for TNBC, are best known to cause dose-dependent, delayed, and progressive cardiomyopathy, often years after treatment. Therefore, the leading cause of death in breast cancer survivors is cardiovascular disease, caused by the same treatment that once saved their lives. Additionally, many patients cannot endure many potential life saving cancer treatments due to reduced cardiovascular health.

NovoMedix has developed oral drugs that co-target key pathways with anti-cancer as well as cardioprotective properties. Preclinical data shows that these molecules have synergistic properties in both primary and metastatic TNBC tumors when used in combination with chemotherapeutic and immune onocology agents while protecting cardiomyocytes and preserving cardiac function. This unique property derived from the co-targeting activity of NovoMedix's drug candidates should significantly improve the clinical outcome of patients as well as the longevity and quality-of-life of breast cancer survivors.

Cardiopulmonary Injuries

The leading cause of mortality in acute respiratory infections, such as severe COVID-19, is complications from Acute Lung Injury/Acute Respiratory Distress Syndrome (ALI/ARDS) resulting in respiratory and/or heart failure. Patients with underlying health conditions (asthma, COPD, obesity, diabetes, heart disease) are at higher risk than others. Further, patients who recover from severe respiratory infections may have damaged lungs and hearts with subclinical persistent injury, which could progress to fibrosis, resulting in long-term adverse outcomes that may require lung and/or heart transplant. NovoMedix clinical candidates have been shown to reduce inflammation and fibrosis in several different animal models of lung and heart injury. These drugs could be used to treat ALI/ARDS and decrease mortality in COVID-19 patients and in future respiratory infections.

Heart disease is the leading cause of death worldwide. One of the major contributors to heart disease, and a predictor of poor clinical outcome, is cardiac fibrosis (scarring of the heart tissue) which leads to heart failure. Most people with heart failure die within 5 years of diagnosis.

Cardiac fibroblasts are the main cell type in the heart and respond to myocardial injury by transforming into hyperactive cells known as myofibroblasts which deposit connective tissue (collagen and other matrix proteins) to form a scar to heal wounds. Under normal circumstances, myofibroblasts disappear once the wound is healed. In hypertensive heart disease, the injury is chronic, leading to cardiac fibrosis, the buildup of scar tissue in the heart muscle and valves. The scar tissue is thicker and stiffer than regular tissue, making it difficult for the heart to work properly. The increased load on the heart eventually leads to heart failure. NovoMedix has developed novel clinical candidates with excellent safety profile that inhibit cardiac fibrosis and have shown remarkable efficacy in a mouse model of heart failure.